What is the evidence supporting the use of rituximab in crescentic IgA nephropathy?

Evidence for rituximab in crescentic IgA nephropathy is limited but includes observations of proteinuria reduction and potential relapse risk reduction when combined with corticosteroids compared to steroid monotherapy.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-17
DOI
https://doi.org/10.5281/zenodo.24299560
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

What is the evidence supporting the use of rituximab in crescentic IgA nephropathy?

Tripdatabase
1 links
Zenodo (CERN European Organization for Nuclear Research)
Renal Diseases and Glomerulopathies
article

What is the evidence supporting the use of rituximab in crescentic IgA nephropathy?

Tripdatabase
article en

Abstract

Evidence for rituximab in crescentic IgA nephropathy is limited but includes observations of proteinuria reduction and potential relapse risk reduction when combined with corticosteroids compared to steroid monotherapy.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon